Cmp Development LLC

Liqmeds Worldwide Limited

Antiop, Inc.

Indivior UK Limited

Michael Paul DeHart

Anthony Pipho

Jayanta Kumar Mandal

Swati Nagar

Malay Patel

Joseph W Wyse

Joseph Wyse

Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Pharmaceutical solution of amlodipine

Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.

Spironolactone aqueous compositions

Disclosed herein is a pharmaceutical composition, comprising: (a) spironolactone; (b) a xanthan gum; (c) an anti-foaming agent; (d) a preservative; (f) a dispersing agent; (g) a sweetening agent; (h) a flavoring agent; (i) optionally a buffer to maintain the pH of the pharmaceutical composition within a range described herein; and (j) a sufficient amount of a water vehicle.

Spironolactone aqueous formulations

Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example, opioid overdose in an individual in need thereof. Also disclosed are methods of making compositions containing Naloxone, and devices for nasal delivery of naloxone compositions.

Growing community of inventors

Winterville, NC, United States of America

Michael Paul DeHart